News
NAMS
26.98
+1.16%
0.31
Weekly Report: what happened at NAMS last week (0803-0807)?
Weekly Report · 4d ago
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TipRanks · 08/07 21:55
NewAmsterdam Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 08/06 17:55
NewAmsterdam Pharma Price Target Cut to $50.00/Share From $51.00 by RBC Capital
Dow Jones · 08/06 17:55
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50
Benzinga · 08/06 17:46
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD)
TipRanks · 08/06 13:30
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 08/06 12:01
Pantginis Reiterates Buy on NewAmsterdam, Maintains $52 12-Month Price Target Amid Key Obicetrapib Catalysts
TipRanks · 08/06 10:36
NewAmsterdam Pharma reports Q2 results
$678.3 million in cash, cash equivalents and marketable securities at June 30, 2026
Seeking Alpha · 08/05 11:47
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Barchart · 08/05 06:00
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 08/04 13:28
Weekly Report: what happened at NAMS last week (0727-0731)?
Weekly Report · 08/03 10:08
Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 07/27 11:55
Weekly Report: what happened at NAMS last week (0720-0724)?
Weekly Report · 07/27 10:12
NewAmsterdam, Menarini Secure Positive CHMP Opinion For Obicetrapib & Evlarco To Treat Cholesterol
NASDAQ · 07/27 07:40
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill
Seeking Alpha · 07/26 03:58
Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)
TipRanks · 07/24 17:20
NewAmsterdam Pharma: Advancing EU Launch and CV Outcomes Pathway Underpins Unchanged $48 Price Target and Buy Rating
TipRanks · 07/24 16:55
NewAmsterdam announces positive CHMP opinion for Ubeslo and Evlarco
TipRanks · 07/24 14:20
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Johnson & Johnson (JNJ)
TipRanks · 07/24 14:01
More
Webull provides a variety of real-time NAMS stock news. You can receive the latest news about NewAmsterdam Pharma Company N.V through multiple platforms. This information may help you make smarter investment decisions.
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.